Browsing by Author "Araneda, S."

Now showing 1 - 5 of 5
  • Thumbnail Image
    Item
  • No Thumbnail Available
    Item
    Distribution and modulation of urocortin mRNA in the brain of female rats
    (2000) Najle, M.I.; Forray Claps, María Inés; Gysling Caselli, Katia; Belmar Canales, Jorge; Araneda, S.
  • Thumbnail Image
    Item
    Late Acute Humoral Rejection in Low-Risk Renal Transplant Recipients Induced With an Interleukin-2 Receptor Antagonist and Maintained With Standard Therapy: Preliminary Communication
    (ELSEVIER SCIENCE INC, 2011) Morales, J.; Contreras, L.; Zehnder, C.; Pinto, V.; Elberg, M.; Araneda, S.; Herzog, C.; Calabran, L.; Aguilo, J.; Ferrario, M.; Buckel, E.; Fierro, J. A.
    Low-risk renal transplant recipients treated with standard immunosuppressive therapy including interleukin-2 receptor (IL-2R) antagonist show a low incidence of early rejection episodes but few reports have examined the incidence and severity of late rejection processes. This study evaluated retrospectively cellular and antibody-mediated rejection (AMR) among 42 recipients selected because they showed low panel-reactive-antibodies, short cold ischemia time, no delayed graft function, and therapy including basiliximab (Simulect) induction. The mean observation time was 6.6 years. Sixty-seven percent of donors were deceased. Ten-year patient and death-censored graft survivals were 81% and 78%, respectively. Seven patients lost their kidneys due to nonimmunologic events. The seven recipients who experienced cellular rejection episodes during the first posttransplant year had them reversed with steroids. Five patients displayed late acute AMR causing functional deterioration in four cases including 1 graft loss. De novo sensitization occurred in 48% of recipients including patients without clinical rejection. In conclusion, long-term follow-up of kidney transplant recipients selected by a low immunologic risk showed a persistent risk of de novo sensitization evolving to acute AMR in 11% of cases. Although immunologic events were related to late immunosuppressive reduction, most graft losses were due to nonimmunologic factors.
  • Thumbnail Image
    Item
  • No Thumbnail Available
    Item
    Stereological Quantification of Extraocular Muscles in Humans
    (2021) San-Martin, J.; Luna, C.; Garreton, R.; Araneda, S.; Salgado, C.; Rodriguez, A.; Salgado, G.
    The aim of this study is to quantify muscular and connective tissue volumes of extraocular muscles (EOM) in humans with no ophthalmological disease using stereology. EOM from five cadaveric non-strabismic humans were obtained. The number of muscle fibers in 5,000 mu m(2) and volume density (Vv) of muscle and collagen were measured using stereology. Comparisons between antagonist EOM were conducted using Wilcoxon signed rank test for paired samples. A secondary analysis examining differences between pairs of EOM was also conducted. Bilateral tests were performed, and significance was set at 0.05. The horizontal rectus muscles (medial and lateral rectus) had the highest Vv of muscle and the lowest Vv of collagen. The inferior rectus muscle tended to have a fewer number of fibers per 5,000 mu m(2) than the rest of the EOM. However, these differences did not reach statistical significance. This is the first published study describing the normal histology of human EOM using stereology. Our investigation, through the quantification of the proportion of muscle and collagen tissue, as well as the number of muscle fibers in 5,000 mu(2), establishes normal stereological parameters for EOM of humans without ophthalmological disease.